N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine

BIIB122, also known as N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine, is currently being studied in clinical trials for its potential in treating Parkinson’s Disease. These trials aim to evaluate the drug’s efficacy, safety, and effects on patients with different forms of Parkinson’s Disease, including those with specific genetic mutations. The studies are designed to provide valuable insights into BIIB122’s potential as a new treatment option for this challenging neurological condition.

Related diseases and areas:

• Parkinson’s disease

Nacubactam

Nacubactam is an innovative drug currently being studied in clinical trials for the treatment of serious bacterial infections. This article explores the ongoing research into Nacubactam’s effectiveness, safety, and potential applications in combating various types of infections, particularly those caused by antibiotic-resistant bacteria.

Related diseases and areas:

• Pyelonephritis
• Abdominal infection
• Pneumonia bacterial
• Pyelonephritis acute

Nacystelyn

Nacystelyn (NAL), a mucolytic drug, is currently being studied in clinical trials for its potential benefits in treating Obstructive Sleep Apnea (OSA). This article explores the ongoing research on NAL’s effectiveness, safety, and impact on various sleep-related parameters in patients with OSA. The trials aim to assess whether NAL, administered through a dry-powder inhaler, can improve sleep quality and reduce the severity of OSA symptoms.

Related diseases and areas:

• Obstructive sleep apnoea sy…

NADOFARAGENE FIRADENOVEC

Nadofaragene firadenovec (also called Adstiladrin) is being studied in clinical trials for some types of urothelial cancer, especially non-muscle invasive bladder cancer (NMIBC). These trials look at how well it works when placed into the bladder every few months, how long responses last, and how it compares with observation or other standard treatments. Some studies also test it in the upper urinary tract (the renal pelvis) for low-grade upper tract urothelial carcinoma.

Related diseases and areas:

• Bladder transitional cell c…
• Transitional cell carcinoma
• Bladder cancer

Nadunolimab

Nadunolimab, also known as CAN04, is an innovative drug currently being studied in clinical trials for the treatment of various types of cancer. This fully humanized monoclonal antibody targets IL1RAP (Interleukin 1 Receptor Accessory Protein) and is being tested in combination with standard chemotherapy regimens. The trials aim to evaluate its safety, efficacy, and potential benefits for patients with advanced solid tumors, including triple-negative breast cancer, colorectal cancer, non-small cell lung cancer, and biliary tract cancer.

Related diseases and areas:

• Triple negative breast cancer

NALDEMEDINE

Naldemedine is a medication being studied as a treatment for opioid-induced constipation (OIC), a common side effect experienced by patients taking opioid medications for pain management. As a peripherally acting μ-opioid receptor antagonist (PAMORA), naldemedine works by blocking opioid receptors in the gastrointestinal tract without affecting pain relief. Clinical trials are investigating the safety and effectiveness of naldemedine across different patient populations, including adults with chronic non-cancer pain, cancer patients, and even children. This article explores the current research on naldemedine and what it may mean for patients suffering from opioid-related digestive issues.

NALOXEGOL

Naloxegol is a peripherally acting mu-opioid receptor antagonist designed to treat opioid-induced constipation (OIC) without affecting pain relief. Clinical trials have investigated naloxegol in various patient populations receiving opioid therapy, including those with chronic non-cancer pain, cancer-related pain, and post-surgical patients. These studies have examined naloxegol’s effectiveness in improving bowel function, its safety profile, and its pharmacokinetic properties. This article provides an overview of key clinical trials that have evaluated naloxegol’s efficacy, safety, and patient outcomes in treating opioid-induced constipation.

Related diseases and areas:

• Constipation

Naloxegol Oxalate

A clinical trial is underway to investigate the effectiveness of Naloxegol Oxalate, marketed as Moventig, in preventing opioid-induced gastrointestinal motility disturbances in patients with brain injuries. This study, known as the NIPA study, aims to evaluate how Naloxegol administration affects early constipation and ventilator-associated pneumonia in intensive care unit patients receiving opioid medications for pain management.

Related diseases and areas:

• Head injury
• Gastrointestinal motility d…
• Meningorrhagia

Namilumab

Namilumab is an investigational drug being studied in clinical trials for various inflammatory conditions, including rheumatoid arthritis, psoriasis, and sarcoidosis. This article summarizes key findings from recent clinical trials evaluating the efficacy and safety of namilumab in treating these disorders. The trials explore different dosing regimens and compare namilumab to existing treatments, providing valuable insights into its potential as a new therapeutic option.

Related diseases and areas:

• Pulmonary sarcoidosis

Namodenoson

Namodenoson, also known as CF102, is an experimental drug currently being studied in clinical trials for its potential in treating various cancers and liver conditions. This article explores the ongoing research on Namodenoson, focusing on its use in advanced pancreatic cancer, non-alcoholic steatohepatitis (NASH), and advanced hepatocellular carcinoma (liver cancer) in patients with cirrhosis. These trials aim to evaluate the safety, efficacy, and potential benefits of Namodenoson in improving patient outcomes and quality of life.

Nanatinostat

Nanatinostat is an experimental drug being studied in clinical trials for the treatment of various cancers associated with the Epstein-Barr virus (EBV). This article explores the ongoing research into Nanatinostat’s potential as a treatment option for EBV-positive solid tumors, lymphomas, and other related conditions. We’ll look at how Nanatinostat works, its combination with other drugs, and the current state of clinical trials investigating its safety and effectiveness.

Related diseases and areas:

• Epstein-Barr virus associat…

Nandrolone Decanoate

Nandrolone Decanoate, an anabolic steroid, has been the subject of several clinical trials exploring its potential benefits in various medical conditions. These trials aim to evaluate its effectiveness in treating conditions such as muscle wasting, bone marrow failure, cancer-induced malnutrition, and sarcopenia. Researchers are also investigating its use in improving outcomes after surgeries and as a potential male contraceptive. This article summarizes the key findings and ongoing research on Nandrolone Decanoate in clinical trials.

Nanobody Against Macrophage Mannose Receptor, Conjugated With 1,4,7-Triazacyclononane-N,N’,N”-Triacetic Acid, Labelled With Gallium Ga-68

Clinical trials are currently underway to investigate the use of a novel imaging agent called 68Ga-NOTA-Anti-MMR-VHH2 in patients with cardiac sarcoidosis and non-small cell lung cancer (NSCLC). This innovative drug is designed to detect specific types of immune cells called macrophages, which play a crucial role in these diseases. The trials aim to evaluate the effectiveness and safety of this imaging technique in diagnosing and monitoring these conditions, potentially offering new insights into disease progression and treatment response.

Related diseases and areas:

• Non-small cell lung cancer
• Cardiac sarcoidosis

Napabucasin

Napabucasin, also known as BBI-608, is an investigational drug being studied in various clinical trials for its potential in treating different types of cancer. These trials aim to evaluate the safety, efficacy, and optimal dosing of Napabucasin, both as a standalone treatment and in combination with other cancer therapies. The drug is being tested in patients with advanced malignancies, including colorectal cancer, pancreatic cancer, and non-small cell lung cancer.

Related diseases and areas:

• Pancreatic carcinoma metast…
• Colorectal cancer metastatic

Naporafenib

Naporafenib, also known as ERAS-254 or LXH254, is an experimental Pan-Raf inhibitor being studied in clinical trials for the treatment of advanced or metastatic solid tumors and NRAS-mutant melanoma. These trials aim to evaluate the safety, efficacy, and potential benefits of combining Naporafenib with other drugs, particularly Trametinib, in patients who have not responded to standard therapies or for whom no standard therapy exists.

Related diseases and areas:

• Neoplasm malignant
• Neoplasm
• Metastatic malignant melanoma
• Malignant melanoma

Naproxen Sodium

This article examines various clinical trials investigating the use of Naproxen Sodium, a nonsteroidal anti-inflammatory drug (NSAID), in managing different types of pain. The studies explore its effectiveness, safety profile, and potential combinations with other medications for enhanced pain relief. These trials provide valuable insights into the drug’s role in treating conditions such as migraine, dental pain, and chronic pain disorders.

Related diseases and areas:

• Osteoarthritis
• Axial spondyloarthritis
• Endometriosis

Naronapride Dihydrochloride Trihydrate

A clinical trial is underway to assess the effectiveness and safety of Naronapride Dihydrochloride Trihydrate, a potential treatment for moderate idiopathic or diabetic gastroparesis. This phase IIb study aims to determine the optimal dose and evaluate the drug’s impact on symptoms associated with delayed stomach emptying. The trial involves a 12-week treatment period and compares the effects of Naronapride to a placebo in adult participants.

Related diseases and areas:

• Impaired gastric emptying
• Diabetic gastroparesis

Narsoplimab

Narsoplimab is an investigational drug currently being studied in clinical trials for its potential to treat thrombotic microangiopathies (TMA) associated with hematopoietic stem cell transplantation (HSCT). These trials aim to evaluate the safety, efficacy, and other important aspects of Narsoplimab in both pediatric and adult patients who have developed this serious complication following stem cell transplants.

Related diseases and areas:

• Stem cell transplant
• Coagulopathy
• Thrombotic microangiopathy

Natalizumab

This article explores the use of Natalizumab (also known as Tysabri) in clinical trials for the treatment of multiple sclerosis (MS). Natalizumab is being studied in various forms of MS, including relapsing-remitting, primary progressive, and secondary progressive types. The trials aim to evaluate the drug’s safety, efficacy, and optimal dosing strategies. Some studies are also investigating Natalizumab’s potential in treating other conditions like pulmonary metastatic osteosarcoma.

Related diseases and areas:

• Secondary progressive multi…
• Primary progressive multipl…
• Progressive multiple sclerosis
• Multiple sclerosis
• Nervous system disorder
• Relapsing-remitting multipl…

NAVENIBART

NAVENIBART is an investigational drug currently being evaluated in clinical trials for the prevention of attacks in people with Hereditary Angioedema (HAE). This rare genetic condition causes episodes of severe swelling in various parts of the body. A Phase 3 clinical trial is currently assessing different dosing regimens of NAVENIBART given as subcutaneous injections to determine its safety and effectiveness compared to placebo. The study aims to evaluate how well NAVENIBART reduces the frequency of HAE attacks and improves quality of life for both adult and adolescent participants with type 1 or type 2 HAE.

Related diseases and areas:

• Hereditary angioedema

Navitoclax

Navitoclax is an investigational drug being studied in clinical trials for various blood cancers and myelofibrosis. This article summarizes key information about ongoing clinical trials evaluating navitoclax alone or in combination with other therapies. The trials aim to assess the safety, efficacy, and optimal dosing of navitoclax in conditions like chronic lymphocytic leukemia, acute lymphoblastic leukemia, and myelofibrosis.

Related diseases and areas:

• Myelofibrosis

Navtemadlin

This article examines the use of Navtemadlin, an experimental MDM2 inhibitor anticancer drug, in various clinical trials. Navtemadlin is being studied for its potential in treating different types of cancer, including endometrial cancer, non-small cell lung cancer, myelofibrosis, leukemia, soft tissue sarcoma, and multiple myeloma. The trials aim to evaluate its safety, efficacy, and optimal dosing when used alone or in combination with other treatments.

Related diseases and areas:

• Endometrial cancer
• Myelofibrosis
• Primary myelofibrosis

Naxitamab

Naxitamab is an innovative drug being studied in clinical trials for the treatment of high-risk neuroblastoma, a rare and aggressive childhood cancer. This article explores how Naxitamab is being used in various clinical trials to improve outcomes for patients with neuroblastoma, particularly those with refractory or relapsed disease. We’ll examine the drug’s potential benefits, its combination with other therapies, and the ongoing research to optimize its use in fighting this challenging cancer.

Related diseases and areas:

• Ewing’s sarcoma
• Neuroblastoma recurrent

Nazartinib

Nazartinib (EGF816) is an investigational drug being studied in clinical trials for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations. This article summarizes key information from clinical trials evaluating nazartinib alone and in combination with other targeted therapies for NSCLC. The trials aim to determine the safety, efficacy, and optimal dosing of nazartinib in different patient populations and treatment settings.

Related diseases and areas:

• Neoplasm malignant

Nebivolol

This article examines the use of Nebivolol, a beta-blocker medication, in various clinical trials. Nebivolol has been studied for its effects on heart health, blood pressure control, and vascular function. The trials explore its potential benefits for conditions like hypertension, heart failure, and coronary artery issues. We’ll look at how Nebivolol compares to other medications and its unique properties that may offer advantages for certain patients.

Related diseases and areas:

• Andersen-Tawil syndrome
• Cardiomyopathy
• Cardiac failure

Nebivolol Hydrochloride

Nebivolol Hydrochloride, a third-generation beta-blocker, is being studied in various clinical trials for its potential benefits in treating cardiovascular conditions. These trials aim to evaluate its effectiveness in managing hypertension, improving heart function, and addressing specific cardiovascular issues like microvascular angina and coronary artery spasms. The unique properties of Nebivolol, including its ability to increase nitric oxide production and its antioxidant effects, make it a promising candidate for improving cardiovascular health in diverse patient populations.

Related diseases and areas:

• Hypertension
• Myocardial infarction

Necvax-Neo1

NECVAX-NEO1 is an innovative drug currently being studied in clinical trials for its potential in treating various types of cancer. These trials aim to assess the safety, tolerability, and effectiveness of NECVAX-NEO1 when used in combination with other cancer treatments, particularly immunotherapy drugs known as PD-1 or PD-L1 inhibitors. The studies focus on patients with advanced solid tumors and triple-negative breast cancer, offering hope for new treatment options in challenging cancer cases.

Related diseases and areas:

• Neoplasm
• Triple negative breast cancer

Nedosiran

Nedosiran is an investigational drug currently being studied in clinical trials for the treatment of Primary Hyperoxaluria (PH), particularly Type 1 (PH1). This article explores the ongoing research on Nedosiran, its potential benefits, and its administration in patients of various ages with PH. The trials aim to evaluate the safety, efficacy, and pharmacokinetics of Nedosiran in both adults and children with this rare genetic disorder.

Related diseases and areas:

• Hyperoxaluria
• Primary hyperoxaluria

Neflamapimod

Neflamapimod is an investigational drug being studied in clinical trials for its potential benefits in treating various neurodegenerative disorders, including dementia with Lewy bodies (DLB), Huntington’s disease, and Alzheimer’s disease. This article summarizes key information from several clinical trials examining the effects of neflamapimod on cognitive function, motor symptoms, and disease biomarkers in patients with these conditions.

Related diseases and areas:

• Dementia with Lewy bodies
• Dementia

Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid

Clinical trials are currently underway to evaluate the effectiveness and safety of a quadrivalent meningococcal conjugate vaccine containing Neisseria Meningitidis Serogroup C polysaccharide conjugated to tetanus toxoid. These studies aim to improve protection against meningococcal disease, particularly in infants and young children. The trials are comparing the new vaccine to existing vaccines and assessing immune responses, safety profiles, and dosing schedules to optimize vaccination strategies.

Related diseases and areas:

• Meningococcal infection
• Chronic spontaneous urticaria

Nelarabine

Nelarabine, also known as Arranon or compound 506U78, is an investigational drug being studied in clinical trials for various T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). This article explores the ongoing research into nelarabine’s safety, efficacy, and potential applications in treating these challenging blood cancers.

Related diseases and areas:

• Malignant melanoma
• Breast cancer

Nemolizumab

Nemolizumab is an investigational drug being studied in clinical trials for its potential to treat various skin conditions, primarily moderate-to-severe atopic dermatitis. This article summarizes key findings from recent clinical trials evaluating the efficacy and safety of nemolizumab for atopic dermatitis and other dermatological disorders.

Related diseases and areas:

• Neurodermatitis
• Dermatitis atopic

Nemtabrutinib

Nemtabrutinib, also known as MK-1026 or ARQ 531, is an investigational drug being studied in clinical trials for the treatment of various hematologic malignancies. These trials aim to evaluate the safety, efficacy, and pharmacokinetics of nemtabrutinib in patients with conditions such as chronic lymphocytic leukemia, lymphomas, and other blood cancers. The research focuses on understanding how the drug works in the body and its potential benefits for patients who have not responded well to other treatments.

Related diseases and areas:

• Richter’s syndrome
• Haematological malignancy
• Follicular lymphoma
• Chronic lymphocytic leukaemia
• Mantle cell lymphoma
• B-cell small lymphocytic ly…

Nemvaleukin Alfa

Nemvaleukin Alfa is an innovative drug currently being studied in clinical trials for the treatment of advanced cancers, including head and neck squamous cell carcinoma, cutaneous melanoma, and mucosal melanoma. These trials aim to evaluate the drug’s effectiveness, safety, and potential benefits when used alone or in combination with other cancer treatments. The ongoing research provides hope for patients with these challenging cancers and may lead to new treatment options in the future.

Related diseases and areas:

• Ovarian cancer
• Metastatic malignant melanoma
• Fallopian tube cancer
• Peritoneal cancer index

Neob

NeoB is an investigational drug being studied in clinical trials for various advanced solid tumors. It targets a protein called gastrin-releasing peptide receptor (GRPR), which is overexpressed in certain cancers. The trials are evaluating NeoB as both an imaging agent ([68Ga]Ga-NeoB) and a therapeutic agent ([177Lu]Lu-NeoB) to detect and treat GRPR-positive tumors. These studies aim to determine the safety, efficacy, and optimal dosing of NeoB in different cancer types and treatment combinations.

Related diseases and areas:

• Breast cancer metastatic
• Neoplasm malignant

Neomycin Sulfate

Neomycin Sulfate, an antibiotic commonly used to treat infections, is being studied in several clinical trials for its potential in treating various medical conditions. These trials aim to explore the drug’s effectiveness in areas such as decolonization of resistant bacteria, prevention of surgical site infections, and its impact on gut microbiome and metabolic health.

Related diseases and areas:

• Bacterial vaginosis
• Retinitis pigmentosa
• Vulvovaginal candidiasis

Nepafenac

Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) used in ophthalmic treatments. This article examines various clinical trials investigating the efficacy and safety of Nepafenac in managing ocular conditions, particularly in relation to cataract surgery and diabetic macular edema. We’ll explore how Nepafenac compares to other treatments and its potential benefits in reducing inflammation and preventing complications in eye surgeries.

Related diseases and areas:

• Cataract
• Corneal dystrophy

Neratinib

Neratinib is an investigational drug being studied in various clinical trials for its potential in treating different types of cancer, particularly HER2-positive breast cancer. This article explores the ongoing research on Neratinib, its applications, and its effects on patients in clinical trial settings.

Related diseases and areas:

• HER2 positive breast cancer
• Biliary neoplasm
• Hormone receptor positive b…

Nesolicaftor

Nesolicaftor, also known as PTI-428, is a promising drug being studied in clinical trials for the treatment of cystic fibrosis (CF). These trials aim to evaluate the safety and effectiveness of Nesolicaftor when used in combination with other drugs (Dirocaftor and Posenacaftor) in adults with CF who have rare genetic mutations. The studies are designed to help researchers understand how well this drug combination works in improving lung function and other important aspects of CF management.

Related diseases and areas:

• Cystic fibrosis

Netupitant

Netupitant is an innovative drug being studied in clinical trials for its effectiveness in preventing chemotherapy-induced nausea and vomiting (CINV). This article explores how netupitant, often combined with other antiemetic medications, is being tested to improve the quality of life for cancer patients undergoing chemotherapy. The trials focus on different patient populations, dosages, and combinations to determine the optimal use of netupitant in managing CINV.

Related diseases and areas:

• Malignant peritoneal neoplasm
• Papillary serous endometria…
• Ovarian cancer
• Fallopian tube cancer
• Prophylaxis of nausea and v…
• Thrombocytopenia

Ng004

A groundbreaking clinical trial is underway to investigate the potential of NG004, a human monoclonal antibody, in treating acute spinal cord injuries. This first-in-human study aims to evaluate the safety, tolerability, and effectiveness of NG004 when administered intrathecally (directly into the spinal fluid) to patients with acute incomplete cervical spinal cord injuries. The trial will assess multiple doses of NG004 and determine the maximum tolerated dose, potentially paving the way for a new treatment option in spinal cord injury care.

Related diseases and areas:

• Spinal cord injury cervical

Ngi226

A new clinical trial is exploring the potential of NGI226 microparticles as a treatment for Achilles tendinopathy. This study aims to evaluate the safety, tolerability, and preliminary effectiveness of NGI226 when administered as a single peritendon injection. The trial compares NGI226 to a placebo in patients suffering from mid-portion Achilles tendinopathy, focusing on both local and systemic effects, as well as improvements in tendon mechanical properties.

Ngm707

NGM707 is an innovative drug currently being studied in clinical trials for the treatment of various advanced or metastatic solid tumor malignancies. This article explores the ongoing research on NGM707, both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®), to evaluate its safety, efficacy, and potential benefits for patients with different types of cancer.

Related diseases and areas:

• Neoplasm